Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Bull World Health Organ
; 63(3): 513-9, 1985.
Article
em En
| MEDLINE
| ID: mdl-2931206
The preliminary results of a study of the incidence of breast cancer in relation to use of depot-medroxyprogesterone acetate (DMPA) are presented. The findings are based on data from three participating centres in Thailand, and one each in Kenya and Mexico. A relative risk for breast cancer of 0.7 was observed in women who had ever used DMPA; this was not statistically significant. Although no consistent decrease in risk with duration of use was observed, the lowest relative risk (0.5) was observed in women who had used DMPA for three or more years. These findings are based on small numbers and must be considered preliminary. However, they provide no evidence that DMPA increases the risk of breast cancer, and suggest that it may exert a protective effect, particularly in long-term users.
Palavras-chave
Africa; Africa South Of The Sahara; Americas; Asia; Breast Cancer; Cancer; Central America; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Depo-provera--side effects; Developed Countries; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Family Planning; Incidence; Kenya; Latin America; Measurement; Medroxyprogesterone Acetate--side effects; Mexico; Neoplasms; North America; Research Methodology; Southeastern Asia; Thailand
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Anticoncepcionais Femininos
/
Medroxiprogesterona
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
País/Região como assunto:
Africa
/
Asia
/
Mexico
Idioma:
En
Revista:
Bull World Health Organ
Ano de publicação:
1985
Tipo de documento:
Article
País de publicação:
Suíça